Redeye is left feeling encouraged following the news that the FDA has, following its initial review, agreed to conduct a comprehensive review of the Dasynoc application under the 505(b)(2) process.
ANNONS
Redeye is left feeling encouraged following the news that the FDA has, following its initial review, agreed to conduct a comprehensive review of the Dasynoc application under the 505(b)(2) process.